Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence

BJU International
Mohammed AlshalalfaElai Davicioni

Abstract

To better characterize the genomics of patients with biochemical recurrence (BCR) who have metastatic disease progression in order to improve treatment decisions for prostate cancer. The expression profiles of three clinical outcome groups after radical prostatectomy (RP) were compared: those with no evidence of disease (NED; n = 108); those with BCR (rise in prostate-specific antigen [PSA] level without metastasis; n = 163); and those with metastasis (n = 192). The patients were profiled using Human Exon 1.0 ST microarrays, and outcomes were supported by a median 18 years of follow-up. A metastasis signature was defined and verified in an independent RP cohort to ensure the robustness of the signature. Furthermore, bioinformatics characterization of the signature was conducted to decipher its biology. Minimal gene expression differences were observed between adjuvant treatment-naïve patients in the NED group and patients without metastasis in the BCR group. More than 95% of the differentially expressed genes (metastasis signature) were found in comparisons between primary tumours of metastasis patients and the two other outcome groups. The metastasis signature was validated in an independent cohort and was significantly associ...Continue Reading

References

Oct 29, 2003·Molecular Cell·Richard BaylissElena Conti
Jun 15, 2004·The Journal of Biological Chemistry·Yu-Gang WangKaren M Frank
Jun 10, 2005·FEBS Letters·Manuela Baccarini
Dec 17, 2009·Bioinformatics·Maureen A SartorGilbert S Omenn
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergPeter R Carroll
Jun 29, 2010·Cancer Cell·Barry S TaylorWilliam L Gerald
Jul 19, 2011·Expert Review of Endocrinology & Metabolism·Jason L NellesGail S Prins
Mar 1, 2012·Frontiers in Genetics·Ismael A VergaraElai Davicioni
Mar 6, 2012·European Urology·Patrick J BastianMichael J Zelefsky
Mar 31, 2012·Science Translational Medicine·John R PrensnerArul M Chinnaiyan
May 16, 2012·Cancer Discovery·Ana AparicioSankar N Maity
Jun 2, 2012·Journal of Biomolecular Screening·Catherine Bardelle, Joanna Boros
Jul 19, 2014·International Journal of Radiation Oncology, Biology, Physics·Robert B DenAdam P Dicker
Oct 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jing XiaRuth Etzioni

❮ Previous
Next ❯

Citations

Aug 13, 2015·Current Urology Reports·Martin SpahnR Jeffrey Karnes
Mar 10, 2017·Expert Review of Molecular Diagnostics·Michele ColicchiaR Jeffrey Karnes
May 20, 2017·Oncology Letters·Yanling Liu
Feb 22, 2017·Current Oncology Reports·Jamil S SyedPreston C Sprenkle
Apr 23, 2015·Biology of the Cell·Mohammed AlshalalfaElai Davicioni
Mar 15, 2016·Current Opinion in Oncology·Neil E Martin
Aug 7, 2021·Journal of Personalized Medicine·James MeehanArran K Turnbull

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.